FindTrial
Sign In

LP-108

DRUG2 trials

Sponsors

Newave Pharmaceutical Inc, Guangzhou Lupeng Pharmaceutical Company LTD.

Conditions

AML/MDSAcute Myeloid LeukemiaCMMLChronic Myelomonocytic LeukemiaMyelodysplastic SyndromesRefractory Acute Lymphoblastic LeukemiaRelapseRelapse Leukemia

Phase 1

Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
CompletedNCT04139434
Newave Pharmaceutical IncAML/MDS, CMML, Refractory Acute Lymphoblastic Leukemia +3
Start: 2020-07-06End: 2025-12-19Updated: 2026-01-23
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
RecruitingNCT05641259
Guangzhou Lupeng Pharmaceutical Company LTD.Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Start: 2023-02-14End: 2028-12-31Target: 198Updated: 2026-09-11

Related Papers

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 (Lacutoclax) As Monotherapy and in Combination with Azacitidine in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Blood2024-11-05
P492: SAFETY AND EFFICACY OF LP-108 AS MONOTHERAPY AND COMBINED WITH AZACITIDINE IN PATIENTS WITH RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR ACUTE MYELOID LEUKEMIA
HemaSphere2023-08-011 citations
Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
Journal of Clinical Oncology2022-06-014 citations